Replimune Group, Inc.

REPL · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
163
SEC Filings

Business Summary

Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment. Its proprietary RPx platform is based on an engineered HSV-1 backbone designed to maximize immunogenic cell death and systemic anti-tumor immune response. Lead product RP1 (vusolimogene oderparepvec) is being evaluated in melanoma and non-melanoma skin cancers, with a BLA submitted to the FDA in combination with nivolumab for anti-PD-1 failed advanced melanoma, granted priority review with a PDUFA date of July 22, 2025.

Next Earnings

Q2 FY2026 — expected 2026-09-10

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionREPLdiscussed_in_filing Cybersecurity
topic_mentionREPLdiscussed_in_filing Trusted Computing
topic_mentionREPLdiscussed_in_filing Blockchain & Crypto
topic_mentionREPLdiscussed_in_filing Regulation
topic_mentionREPLdiscussed_in_filing Healthcare & Bio
topic_mentionREPLdiscussed_in_filing Platform & Ecosystem
topic_mentionREPLdiscussed_in_filing Sovereign & Government
topic_mentionREPLdiscussed_in_filing Cybersecurity
topic_mentionREPLdiscussed_in_filing Trusted Computing
topic_mentionREPLdiscussed_in_filing Blockchain & Crypto
topic_mentionREPLdiscussed_in_filing Regulation
topic_mentionREPLdiscussed_in_filing Healthcare & Bio
topic_mentionREPLdiscussed_in_filing Platform & Ecosystem
topic_mentionREPLdiscussed_in_filing Sovereign & Government
topic_mentionREPLdiscussed_in_filing Cybersecurity
topic_mentionREPLdiscussed_in_filing Trusted Computing
topic_mentionREPLdiscussed_in_filing Blockchain & Crypto
topic_mentionREPLdiscussed_in_filing Regulation
topic_mentionREPLdiscussed_in_filing Healthcare & Bio
topic_mentionREPLdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-05-222025-03-310001737953-25-000009EDGAR79K words
2024-05-162024-03-310001737953-24-000008EDGAR—
2023-05-182023-03-310001737953-23-000009EDGAR—
2022-05-192022-03-310001737953-22-000010EDGAR—
2021-05-202021-03-310001104659-21-069611EDGAR—
2020-06-032020-03-310001047469-20-003318EDGAR—
2019-06-282019-03-310001047469-19-003946EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-032025-12-310001628280-26-004805EDGAR55K words
2025-11-062025-09-300001628280-25-049884EDGAR—
2025-08-072025-06-300001737953-25-000013EDGAR—
2025-02-122024-12-310001737953-25-000004EDGAR—
2024-11-122024-09-300001737953-24-000015EDGAR—
2024-08-082024-06-300001737953-24-000013EDGAR—
2024-02-082023-12-310001737953-24-000004EDGAR—
2023-11-072023-09-300001737953-23-000017EDGAR—
2023-08-032023-06-300001737953-23-000013EDGAR—
2023-02-092022-12-310001737953-23-000005EDGAR—
2022-11-032022-09-300001737953-22-000023EDGAR—
2022-08-042022-06-300001737953-22-000014EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-030001104659-26-009510EDGAR2K words
2026-01-120001104659-26-002721EDGAR—
2025-11-060001104659-25-107438EDGAR—
2025-10-200001104659-25-100605EDGAR—
2025-09-180001104659-25-091066EDGAR—
2025-09-040001104659-25-087464EDGAR—
2025-08-070001104659-25-074989EDGAR—
2025-07-220001104659-25-069489EDGAR—
2025-06-240001104659-25-062122EDGAR—
2025-05-220001104659-25-051847EDGAR—

163 total filings indexed. 134 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Tags

oncology immuno-oncology skin-cancer-(melanoma,-nmsc,-cscc,-mcc,-basal-cell-carcinoma,-angiosarcoma) solid-organ-transplant-recipients-with-skin-cancers recist-1.1 modified-recist-1.1 accelerated-approval-pathway-(fda) biologics-license-application-(bla) breakthrough-therapy-designation priority-review

Company Identity

CIK0001737953
TickerREPL
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: e24efb4a0c109b66ad0babcb49b1cc37acc85021a28bd90551b766244b4c9da6
parent: ad14a8af0587ac38a44bf82770826066611256958fa917f313dc5e285ed8ecc0
content hash: a7fa92c995e6650c54cee00e9685b5efaf8617abc7c9c43614bf3891821bcffa
signed: 2026-04-13T04:47:10.144Z
sources: 19 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf